Cargando…

The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society

In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs),...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Byung Chun, Kim, Nam Ho, Nam, Gi Byung, Park, Hyung Wook, On, Young Keun, Lee, Young Soo, Lim, Hong Euy, Joung, Boyoung, Cha, Tae Joon, Hwang, Gyo Seung, Oh, Seil, Kim, June Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310986/
https://www.ncbi.nlm.nih.gov/pubmed/25653698
http://dx.doi.org/10.4070/kcj.2015.45.1.9
_version_ 1782354938277396480
author Jung, Byung Chun
Kim, Nam Ho
Nam, Gi Byung
Park, Hyung Wook
On, Young Keun
Lee, Young Soo
Lim, Hong Euy
Joung, Boyoung
Cha, Tae Joon
Hwang, Gyo Seung
Oh, Seil
Kim, June Soo
author_facet Jung, Byung Chun
Kim, Nam Ho
Nam, Gi Byung
Park, Hyung Wook
On, Young Keun
Lee, Young Soo
Lim, Hong Euy
Joung, Boyoung
Cha, Tae Joon
Hwang, Gyo Seung
Oh, Seil
Kim, June Soo
author_sort Jung, Byung Chun
collection PubMed
description In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs), the strategy for antithrombotic therapy has undergone significant changes due to its superior efficacy, safety and convenience compared with warfarin. Furthermore, new aspects of antithrombotic therapy and risk assessment of stroke have been revealed: the efficacy of stroke prevention with aspirin is weak, while the risk of major bleeding is not significantly different from that of oral anticoagulant (OAC) therapy, especially in the elderly. Reflecting these pivotal aspects, previous guidelines have been updated in recent years by overseas societies and associations. The Korean Heart Rhythm Society has summarized the new evidence and updated recommendations for stroke prevention of patients with nonvalvular AF. First of all, antithrombotic therapy must be considered carefully and incorporate the clinical characteristics and circumstances of each individual patient, especially with regards to balancing the benefits of stroke prevention with the risk of bleeding, recommending the CHA(2)DS(2)-VASc score rather than the CHADS(2) score for assessing the risk of stroke, and employing the HAS-BLED score to validate bleeding risk. In patients with truly low risk (lone AF, CHA(2)DS(2)-VASc score of 0), no antithrombotic therapy is recommended, whereas OAC therapy, including warfarin (international normalized ratio 2-3) or NOACs, is recommended for patients with a CHA(2)DS(2)-VASc score ≥2 unless contraindicated. In patients with a CHA(2)DS(2)-VASc score of 1, OAC therapy should be preferentially considered, but depending on bleeding risk or patient preferences, antiplatelet therapy or no therapy could be permitted.
format Online
Article
Text
id pubmed-4310986
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-43109862015-02-04 The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society Jung, Byung Chun Kim, Nam Ho Nam, Gi Byung Park, Hyung Wook On, Young Keun Lee, Young Soo Lim, Hong Euy Joung, Boyoung Cha, Tae Joon Hwang, Gyo Seung Oh, Seil Kim, June Soo Korean Circ J Review Article In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs), the strategy for antithrombotic therapy has undergone significant changes due to its superior efficacy, safety and convenience compared with warfarin. Furthermore, new aspects of antithrombotic therapy and risk assessment of stroke have been revealed: the efficacy of stroke prevention with aspirin is weak, while the risk of major bleeding is not significantly different from that of oral anticoagulant (OAC) therapy, especially in the elderly. Reflecting these pivotal aspects, previous guidelines have been updated in recent years by overseas societies and associations. The Korean Heart Rhythm Society has summarized the new evidence and updated recommendations for stroke prevention of patients with nonvalvular AF. First of all, antithrombotic therapy must be considered carefully and incorporate the clinical characteristics and circumstances of each individual patient, especially with regards to balancing the benefits of stroke prevention with the risk of bleeding, recommending the CHA(2)DS(2)-VASc score rather than the CHADS(2) score for assessing the risk of stroke, and employing the HAS-BLED score to validate bleeding risk. In patients with truly low risk (lone AF, CHA(2)DS(2)-VASc score of 0), no antithrombotic therapy is recommended, whereas OAC therapy, including warfarin (international normalized ratio 2-3) or NOACs, is recommended for patients with a CHA(2)DS(2)-VASc score ≥2 unless contraindicated. In patients with a CHA(2)DS(2)-VASc score of 1, OAC therapy should be preferentially considered, but depending on bleeding risk or patient preferences, antiplatelet therapy or no therapy could be permitted. The Korean Society of Cardiology 2015-01 2015-01-26 /pmc/articles/PMC4310986/ /pubmed/25653698 http://dx.doi.org/10.4070/kcj.2015.45.1.9 Text en Copyright © 2015 The Korean Society of Cardiology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jung, Byung Chun
Kim, Nam Ho
Nam, Gi Byung
Park, Hyung Wook
On, Young Keun
Lee, Young Soo
Lim, Hong Euy
Joung, Boyoung
Cha, Tae Joon
Hwang, Gyo Seung
Oh, Seil
Kim, June Soo
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title_full The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title_fullStr The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title_full_unstemmed The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title_short The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
title_sort korean heart rhythm society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: korean heart rhythm society
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310986/
https://www.ncbi.nlm.nih.gov/pubmed/25653698
http://dx.doi.org/10.4070/kcj.2015.45.1.9
work_keys_str_mv AT jungbyungchun thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT kimnamho thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT namgibyung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT parkhyungwook thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT onyoungkeun thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT leeyoungsoo thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT limhongeuy thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT joungboyoung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT chataejoon thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT hwanggyoseung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT ohseil thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT kimjunesoo thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT jungbyungchun koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT kimnamho koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT namgibyung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT parkhyungwook koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT onyoungkeun koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT leeyoungsoo koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT limhongeuy koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT joungboyoung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT chataejoon koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT hwanggyoseung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT ohseil koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety
AT kimjunesoo koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety